Track 13: Vaccine Safety & Efficacy


Antibody adequacy alludes to the capacity of immunizations to achieve the proposed useful consequences for inoculated people in a characterized populace under perfect states of utilization. The potential advantages of a successful immunization – for example advancement of wellbeing and prosperity, and assurance from ailment and its physical, mental and financial outcomes must be weighed against the potential danger of an antagonistic occasion following vaccination (AEFI) with that immunization. Antibody related hazard is the likelihood of an unfavorable or undesirable result happening, and the seriousness of the subsequent mischief to the wellbeing of inoculated people in a characterized populace following vaccination with an immunization under perfect states of utilization.


  • Influenza Vaccines
  • Measles Vaccines

Related Conference of Track 13: Vaccine Safety & Efficacy

August 22-23, 2022

4th World Congress on Vaccine and Immunology

Toronto, Canada
September 05-06, 2022

42nd Global Summit and Expo on Vaccines & Immunology

Paris, France
November 04-05, 2022

34th Annual Congress on Vaccine and Clinical Trials

Toronto, Canada
November 17-18, 2022

2nd Global Summit on Vaccines and Immunology

Berlin, Germany
February 20-21, 2023

International Conference on Vaccine Research

Madrid, Spain

Track 13: Vaccine Safety & Efficacy Conference Speakers

Recommended Sessions

Related Journals

Are you interested in